Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Multi-Dose Antibiotic Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Rezafungin

NCT04117607
View directory record Official record
Conditions
Fungal Infection
Interventions
Placebo, Rezafungin
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

NCT01934205
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK2140944 (Single dose), GSK2140944 (Multiple dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application

NCT03052842
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Strip, Placebo Strip
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Kalispell, Montana • Bedford, Texas • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 4 Interventional

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

NCT02660346
View directory record Official record
Conditions
Bacteremia
Interventions
Daptomycin, Vancomycin, Ceftaroline
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions
Single-Dose Antibiotic, Multi-Dose Antibiotic
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

NCT04532957
View directory record Official record
Conditions
Healthy
Interventions
KBP-7072, Placebo
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 11, 2026, 5:09 PM EDT
Terminated Not applicable Interventional Results available

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

NCT03341273
View directory record Official record
Conditions
Lower Respiratory Tract Infection
Interventions
Azithromycin, Placebo, VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)
Drug · Other · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 11, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

NCT06321536
View directory record Official record
Conditions
Multi-Drug Resistant Organism Colonization
Interventions
Allogeneic Microbiota in Glycerol (9%) (AMG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Hinsdale, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 11, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

NCT05276401
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Jonesboro, Arkansas • Fresno, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

NCT04380207
View directory record Official record
Conditions
Bacterial Infections
Interventions
QPX7728, Placebo, QPX2014
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 11, 2026, 5:09 PM EDT
Recruiting Phase 3 Interventional

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

NCT06911424
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Fusidic Acid 1%, Placebo
Drug
Lead sponsor
Baxis Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
38
States / cities
Little Rock, Arkansas • Huntington Beach, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

NCT02254993
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 11, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

NCT02214433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Sep 11, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0

NCT06488781
View directory record Official record
Conditions
Obesity in Pregnancy, Labor Complication
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

NCT00488345
View directory record Official record
Conditions
Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions
Tygacil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
8 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Long Beach, California • Oakland, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

NCT03332732
View directory record Official record
Conditions
Bacterial Infections
Interventions
VNRX-5133, VNRX-5022, Metronidazole, Placebo
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

NCT02168946
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 11, 2026, 5:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections

NCT02569541
View directory record Official record
Conditions
Refractory Bone or Joint Infections
Interventions
sodium fusidate
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Fountain Valley, California • San Dimas, California • Sylmar, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 11, 2026, 5:09 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Treatment of Chorioamnionitis After Delivery

NCT00814905
View directory record Official record
Conditions
Chorioamnionitis
Interventions
saline, ampicillin gentamicin, ampicillin gentamicin clindamycin
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 11, 2026, 5:09 PM EDT